Log In
BCIQ
Print this Print this
 

ralimetinib (LY2228820)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionSmall molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK; MAPK14)
Molecular Target p38 mitogen-activated protein kinase (p38 MAPK) (MAPK14)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today